

Life Technologies Corp  
Form 8-K  
September 04, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): September 2, 2009**

**Life Technologies Corporation**

(Exact name of Registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**000-25317**

(Commission  
File Number)

**33-0373077**

(I.R.S. Employer  
Identification Number)

**5791 Van Allen Way  
Carlsbad, CA 92008**

(Address of principal executive offices) (Zip Code)

**(760) 603-7200**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Section 8 Other Events**

**Item 8.01 Other Events**

On September 2, 2009, Life Technologies Corporation, a Delaware corporation (the Company), entered into a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation, a Delaware corporation (Danaher), for \$450 million in cash. On September 2, 2009, the Company posted to the Investor Relations section of its website, <http://www.lifetechnologies.com>, a press release and a replay of its investor conference call held on September 2, 2009, relating to the transaction with Danaher. A replay of this conference call will be available on the Investor Relations section of the Company's website for a period of one week from September 2, 2009.

The Company also provided additional answers to certain follow up questions from the conference call by posting a Questions and Answers document to the Investor Relations section of the Company's website on September 3, 2009. A copy of the Company's Questions and Answers document, which is attached hereto as Exhibit 99.1, will also be available on the Investor Relations section of the Company's website for a period of one week from September 3, 2009.

**Section 9 Financial Statements and Exhibits**

**Item 9.01 Exhibits**

**(d) Exhibits**

**Exhibit 99.1** Questions and Answers, dated September 3, 2009.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LIFE TECHNOLOGIES  
CORPORATION**  
(Registrant)

Date: September 3, 2009

By: /s/ David F. Hoffmeister  
David F. Hoffmeister  
Chief Financial Officer